Gender-specific aspects of treatment of cardiovascular risk factors in primary and secondary prevention

Fundamental and Clinical Pharmacology

Volumn 24, Issue 6, 2010, Pages 699-705

  Lombardi, Mariaelena ^a   Mercuro, Giuseppe ^a   Fini, Massimo ^a   Rosano, Giuseppe M C ^a  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Cardiovascular prevention; Gender; Menopause; Risk factors

Indexed keywords

ACARBOSE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; METFORMIN;

BODY FAT DISTRIBUTION; CARDIOVASCULAR RISK; DIABETES MELLITUS; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR; SEX DIFFERENCE;

CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INCIDENCE; MALE; PRIMARY PREVENTION; RISK FACTORS; RISK REDUCTION BEHAVIOR; SECONDARY PREVENTION; SEX FACTORS;

EID: 78349237841     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2010.00834.x     Document Type: Review

References (56)

1. Collins P., Rosano G., Casey C. et al. Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynecologists. Eur. Heart J. (2007) 28 2028-2040.
2. Piccini JP., Hranitzky P. Diagnostic monitoring strategies in heart failure management. Am Heart J. (2007) 153(4 Suppl) 12-17.
3. Rosamond W., Flegal K., Friday G. et al. for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart Disease and Stroke Statistics 2007 Update. A Report From the American Heart Association Statistics - Committee and Stroke Statistics Subcommittee. Circulation (2007) 115 e69-e171.
4. Vitale C., Mendelshon M.E., Rosano G. Gender differences in the cardiovascular effect of sex hormones. Nat. Rev. Cardiol. (2009) 6 532-542.
5. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur. Heart J. (2001) 22 554-572.
6. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. JAMA (2002) 288, 2998-3007.
7. Harris M.M., Stevens J., Thomas N., Schreiner P., Folsom A.R. Associations of fat distribution and obesity with hypertension in a bi-ethnic population: the ARIC study. Atherosclerosis Risk in Communities Study. Obes. Res. (2000) 8 516-524.
8. Rexrode K.M., Carey V.J., Hennekens C.H. et al. Abdominal adiposity and coronary heart disease in women. JAMA (1998) 280 1843-1848.
9. Kannel W.B., Cupples L.A., Ramaswami R., Stokes J., Kreger B.E., Higgins M. Regional obesity and risk of cardiovascular disease; the Framingham Study. J. Clin. Epidemiol. (1991) 44 183-190.
10. Carr D.B., Utzschneider K.M., Hull R.L. et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes (2004) 53 2087-2094.
11. Yusuf S., Hawken S., Ounpuu S. et al.; INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27, 000 participants from 52 countries: a case-control study. Lancet (2005) 366 1640-1649.
12. Ferrannini E., Natali A., Capaldo B., Lehtovirta M., Jacob S., Yki-Jarvinen H. Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity. European Group for the Study of Insulin Resistance (EGIR). Hypertension (1997) 30 1144-1149.
13. Snyder P.J., Peachey H. Hannoush P. et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J. Clin. Endocrinol. Metab. (1999) 84 2647-2653.
14. Katznelson L., Finkelstein J.S., Schoenfeld D.A., Rosenthal D.I., Anderson E.J., Klibanski A. et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J. Clin. Endocrinol. Metab. (1996) 81 4358-4365.
15. Simon D., Charles M.A., Lahlou N. et al. Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone: a 3-month randomized placebo-controlled trial. Diabetes Care (2001) 24 2149-2151.
16. Kapoor D., Goodwin E., Channer K.S., Jones T.H. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur. J. Endocrinol. (2006) 154 899-906.
17. Wu F.C., Von Eckardstein A. Androgens and coronary artery disease. Endocr. Rev. (2003) 24 183-217.
18. Liu P.Y., Death A.K., Handelsman D.J. Androgens and cardiovascular disease. Endocr. Rev. (2003) 24 313-340.
19. Vogel J.A., Franklin B.A., Zalesin K.C. et al. Reduction in predicted coronary heart disease risk after substantial weight reduction after bariatric surgery. Am. J. Cardiol. (2007) 99 222-226.
20. Sironi A.M., Pingitore A., Ghione S. et al. Early hypertension is associated with reduced regional cardiac function, insulin resistance, epicardial, and visceral fat. Hypertension (2008) 51 282-288.
21. Farpour-Lambert N.J., Aggoun Y., Marchand L.M., Martin X.E., Herrmann F.R., Beghetti M. Physical activity reduces systemic blood pressure and improves early markers of atherosclerosis in pre-pubertal obese children. J. Am. Coll. Cardiol. (2009) 54 396-406.
22. Hu G., Qiao Q., Tuomilehto J. et al. Plasma insulin and cardiovascular mortality in non-diabetic European men and women: a meta-analysis of data from eleven prospective studies. Diabetologia (2004) 47 1245-1256.
23. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet (1998) 352 854-865.
24. Hanefeld M., Schaper F., Koehler C. Effect of acarbose on vascular disease in patients with abnormal glucose tolerance. Cardiovasc. Drugs Ther. (2008) 22 225-231.
25. Chiasson J.L. Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial. Endocr. Pract. (2006) 12(Suppl 1) 25-30.
26. Bosch J., Lonn E., Pogue J. et al. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation (2005) 112 1339-1346.
27. Patel A., MacMahon S., Chalmers J. et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet (2007) 370 829-840.
28. Keech A., Simes R.J., Barter P. et al.; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet (2005) 366 1849-1861.
29. Assmann G., Schulte H. The importance of triglycerides: results from the Prospective Cardiovascular Munster (PROCAM) Study. Eur. J. Epidemiol. (1992) 8(Suppl. 1) 99-103.
30. De Aloysio D., Gambacciani M., Meschia M. et al. The effect of menopause on blood lipid and lipoprotein levels. Atherosclerosis (1999) 147 147-153.
31. Jensen J., Nilas L., Christiansen C. Influence of menopause on serum lipids and lipoproteins. Maturitas (1990) 12 321-331.
32. Shepherd J., Cobbe S.M., Ford I. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. (1995) 333 1301-1307.
33. Petretta M., Costanzo P., Perrone-Filardi P., Chiariello M. Impact of gender in primary prevention of coronary heart disease with statin therapy: a meta-analysis. Int. J. Cardiol. (2010) 138 25-31.
34. Ridker P.M., MacFadyen J.G., Fonseca F.A. et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N. Engl. J. Med. (2008) 359 2195-2207.
35. Downs J.R., Clearfield M., Tyroler H.A. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA (1998) 279 1615-1622.
36. Mizuno K., Nakaya N., Ohashi Y. et al. Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study). Circulation (2008) 4 494-502.
37. Furberg C.D., Adams H.P. Jr, Applegate W.B. et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation (1994) 90 1679-1687.
38. Goldberg R.B., Mellies M.J., Sacks F.M. et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation (1998) 98 2513-2519.
39. Rubins H.B., Robins S.J., Collins D. et al., the VA-HIT Study Group. Diabetes, plasma insulin and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch. Intern. Med. (2002) 162 2597-2604.
40. Cifkova R., Erdine S., Fagard R. et al. Practice Guidelines for Primary Care Physicians: ESH/ESC Hypertension Guidelines. J. Hypertens. (2003) 21, 1779-1786.
41. Sjoberg L., Kaaja R., Tuomilehto J. Epidemiology of postmenopausal hypertension. Int. J. Clin. Pract. (2004) 139(Suppl.) 4-12.
42. Wong N.D., Thakral G., Franklin S.S. et al. Preventing heart disease by controlling hypertension: impact of hypertensive subtype, stage, age, and sex. Am. Heart J. (2003) 145 888-895.
43. Sclavo M. Cardiovascular risk factors and prevention in women: similarities and differences. Ital. Heart. J. (2001) 2(Suppl. 2) 125-141.
44. Wong N.D., Pio J.R., Franklin S.S., L'Italien G.J., Kamath T.V., Williams G.R. et al. Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. Am. J. Cardiol. (2003) 91 1421-1426.
45. Kjeldsen S.E., Julius S. Mancia G. et al.; VALUE Trial Investigators. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J. Hypertens. (2006) 24 1405-1412.
46. Gu Q., Burt V.L., Paulose-Ram R., Yoon S., Gillum R.F. High blood pressure and cardiovascular disease mortality risk among U.S. adults: the third National Health and Nutrition Examination Survey mortality follow-up study. Ann. Epidemiol. (2008) 18 302-309.
47. Turnbull F., Woodward M., Neal B. et al. Blood Pressure Lowering Treatment Trialists' Collaboration. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur. Heart J. (2008) 29 2669-2680.
48. Wilson P.W., Kannel W.B., Silbershatz H., D'Agostino R.B. Clustering of metabolic factors and coronary heart disease. Arch.Intern. Med. (1999) 159 1104-1109.
49. Tuomilehto J., Lindstrom J., Eriksson J.G. et al. Finnish Diabetes Prevention Study Group: prevention of Type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. (2001) 344 1343-1350.
50. Tuomilehto J. Cardiovascular risk: prevention and treatment of the metabolic syndrome. Diabetes Res. Clin. Pract. (2005) 68(Suppl. 2) S28-S35.
51. Manson J.E., Greenland P., LaCroix A.Z. et al. Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N. Engl. J. Med. (2002) 347 716-725.
52. Caminiti G., Volterrani M., Marazzi G. et al. Metabolic syndrome predicts lower functional recovery in female but not in male patients after an acute cardiac event. Int. J. Cardiol. (2009) 135 296-301.
53. Padwal R., Majumdar S.R., Johnson J.A., Varney J., McAlister F.A. A systematic review of drug therapy to delay or prevent Type 2 diabetes. Diabetes Care (2005) 28 736-744.
54. Abuissa H., Bel D.S., O'Keefe J.H. Jr. Strategies to prevent Type 2 Diabetes. Curr. Med. Res. Opin. (2005) 21 1107-1114.
55. Vitale C., Mercuro G., Cornoldi A. et al. Metformin improves endothelial function in patients with metabolic syndrome. J. Intern. Med. (2005) 258 250-256.
56. Scheen A.J. Renin-Angiotensin system inhibition prevention prevents Type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab. (2004) 30 498-505.